<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pituitary</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pituitary</journal-id>
      <journal-title-group>
        <journal-title>Pituitary</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1386-341X</issn>
      <issn pub-type="epub">1573-7403</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24166706</article-id>
      <article-id pub-id-type="pmc">3906545</article-id>
      <article-id pub-id-type="publisher-id">530</article-id>
      <article-id pub-id-type="doi">10.1007/s11102-013-0530-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The role of primary pharmacological therapy in acromegaly</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de los Monteros</surname>
            <given-names>Ana Laura Espinosa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carrasco</surname>
            <given-names>Carmen A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Albarr&#xE1;n</surname>
            <given-names>Alfredo Adolfo Reza</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gadelha</surname>
            <given-names>M&#xF4;nica</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abreu</surname>
            <given-names>Alin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Mercado</surname>
            <given-names>Mois&#xE9;s</given-names>
          </name>
          <address>
            <phone>+52-555281-3029</phone>
            <fax>+52-555281-3085</fax>
            <email>moises.mercado@endocrinologia.org.mx</email>
            <email>mmercadoa@yahoo.com</email>
          </address>
          <xref ref-type="aff" rid="Aff6"/>
          <xref ref-type="aff" rid="Aff7"/>
        </contrib>
        <aff id="Aff1"><label/>Servicio de Endocrinolog&#xED;a, Hospital de Especialidades, Centro M&#xE9;dico Nacional S.XXI, IMSS, Mexico City, Mexico </aff>
        <aff id="Aff2"><label/>Endocrinology Department, Facultad de Medicina, Pontificia Universidad Cat&#xF3;lica de Chile, Santiago, Chile </aff>
        <aff id="Aff3"><label/>Endocrinology and Metabolism Department, Instituto Nacional de Ciencias M&#xE9;dicas y Nutrici&#xF3;n Salvador Zubir&#xE1;n, Mexico City, Mexico </aff>
        <aff id="Aff4"><label/>Endocrinology Section, Hospital Universit&#xE1;rio Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil </aff>
        <aff id="Aff5"><label/>Endocrinology Department, Hospital Imbanaco, Cali, Colombia </aff>
        <aff id="Aff6"><label/>Faculty of Medicine, Universidad Nacional Aut&#xF3;noma de M&#xE9;xico, Mexico City, Mexico </aff>
        <aff id="Aff7"><label/>Endocrine Service, and Experimental Endocrinology Unit, Hospital de Especialidades, Centro M&#xE9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, MD Arist&#xF3;teles 68 Polanco, 11560 Mexico City, Mexico </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>29</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>17</volume>
      <issue>Suppl 1</issue>
      <fpage>4</fpage>
      <lpage>10</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background and objectives</title>
          <p>Primary pharmacological therapy may be the only viable treatment option for many patients with acromegaly, especially those presenting with advanced disease with large inoperable tumors. Long-acting somatostatin analogs are currently the first-line treatment of choice in this setting, where they provide biochemical control and reduce tumor size in a significant proportion of patients. We herein present a brief overview of the role of primary pharmacological therapy in the treatment of acromegaly within the context of Latin America and support this with a representative case study.</p>
        </sec>
        <sec>
          <title>Case description</title>
          <p>A 20&#xA0;year old male presented with clinical and biochemical evidence of acromegaly. The glucose-suppressed growth hormone (GH) was 5.3 &#x3BC;g/L, his insulin-like growth factor-1(IGF-1) was 3.5 times the ULN and serum prolactin greater than 4,000 &#x3BC;g/L. Pituitary MRI revealed a large and invasive mass, extending superiorly into the optic chiasm and laterally into the left cavernous sinus. He was treated with a combination of octreotide and cabergoline with remarkable clinical improvement, normalization of GH and IGF-1 values and striking shrinkage of the adenoma.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This case illustrates how effective the pharmacological therapy of acromegaly can be and yet at the same time, raises several important issues such as the need for life-long treatment with costly medications such as the somatostatin analogs. Access to these agents may be limited in regions where resources are restricted and clinicians face challenges in order to make the most efficient use of available options.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Acromegaly</kwd>
        <kwd>Pituitary</kwd>
        <kwd>Latin America</kwd>
        <kwd>GH</kwd>
        <kwd>IGF-1</kwd>
        <kwd>Somatostatin analogs</kwd>
        <kwd>Dopamine agonists</kwd>
        <kwd>Pegvisomant</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media New York 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="intro">
      <title>Introduction</title>
      <p>Acromegaly is characterized by excessive secretion of growth hormone (GH), usually due to a pituitary tumor, and a subsequent increase in insulin-like growth factor-1 (IGF-1) release from the liver and other tissues [<xref ref-type="bibr" rid="CR1">1</xref>]. Long-term exposure to elevated levels of these two hormones underlies many of the debilitating clinical features of acromegaly, such as arthropathy, cardiomyopathy, diabetes mellitus and sleep apnea [<xref ref-type="bibr" rid="CR1">1</xref>]. Pharmacological intervention in acromegaly is therefore aimed primarily at suppressing secretion of GH from the pituitary or blocking the actions of GH at it receptors, along with a secondary reduction in circulating IGF-1 levels [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Gadolinium-enhanced, T1-weighted MRI scans (coronal view) of pituitary tumor at diagnosis (<italic>left</italic>) and after 6&#xA0;months of treatment with an SSA and dopamine agonist</p></caption><graphic xlink:href="11102_2013_530_Fig1_HTML" id="MO1"/></fig></p>
      <p>There are three classes of pharmacological therapy used routinely to control disease activity in acromegaly: dopamine agonists (principally cabergoline) and somatostatin analogs (SSAs), which suppress the secretion of GH, and a GH receptor antagonist (pegvisomant) [<xref ref-type="bibr" rid="CR2">2</xref>]. However, access to these different classes of drugs may vary at the local level, both between and within individual countries, and this is particularly applicable to Latin America [<xref ref-type="bibr" rid="CR3">3</xref>]. Although pharmacological therapy is used predominantly as secondary therapy for persistent or recurrent acromegaly following non curative surgery, it is increasingly being used as primary therapy in the following situations: (1) patients in whom surgery is not an initial option due to tumor location and limited chance of surgical cure, (2) as short-term therapy before surgery aimed at reducing perioperative anesthetic morbidity, or (3) due to patient preference [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Primary pharmacological therapy may also be appropriate if there are clinical contraindications to surgery or experienced pituitary neurosurgeons are not available. The current article provides a brief overview of the role of primary pharmacological therapy in the treatment of acromegaly in the context of Latin America and supports this with a representative case study.</p>
      <sec id="Sec2">
        <title>Current recommendations for primary pharmacological therapy</title>
        <p>Surgical resection&#x2013;usually, transsphenoidal microscopic or endoscopic surgery (TSS)&#x2013;is recommended as the primary treatment of choice in patients with microadenomas or intrasellar macroadenmas, provided an experienced pituitary neurosurgeon is available to perform the procedure [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. In these situations, surgery can lead to durable clinical, biochemical and tumor volume control of the patient [<xref ref-type="bibr" rid="CR7">7</xref>]. In addition, TSS is indicated in patients with invasive macroadenoma associated with considerable mass effects such as rapidly progressing optic chiasm compression [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Pharmacological therapy is generally used as adjuvant treatment in the setting of persistent disease despite surgical intervention [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>A role for primary pharmacological therapy, especially with SSAs, has been suggested in patients with macroadenomas with stable local mass effects who have a minimal chance of surgical cure (because of extrasellar extension of the tumor, especially into the cavernous sinus) or in patients who are poor surgical candidates or who express a preference for pharmacological treatment [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. In patients with macroadenomas that are not likely to be cured with surgical intervention, debulking surgery may be recommended to improve the response to subsequent pharmacological therapy [<xref ref-type="bibr" rid="CR4">4</xref>]. Radiotherapy is usually reserved as a third-line option for patients with recurrent or persistent disease activity after unsuccessful surgery, and who are resistant or intolerant to pharmacological treatment [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      </sec>
      <sec id="Sec3">
        <title>Options for primary pharmacological therapy</title>
        <p>Currently, long-acting SSAs are generally considered the first choice for the pharmacological treatment of acromegaly [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Long-acting formulations are more widely used due to increased compliance and patient convenience [<xref ref-type="bibr" rid="CR2">2</xref>]. In approximately 50&#xA0;% of cases where SSA primary therapy is used in clinical practice, the indication is the presence of a macroadenoma with lateral extension with or without cavernous sinus invasion, with the remainder of cases being for macroadenoma without compressive symptoms, for elderly patients, or based on patient preference [<xref ref-type="bibr" rid="CR10">10</xref>]. The FDA approved subcutaneous octreotide in 1988, shortly after it was launched in Europe; it became available in Latin America in the early 1990s. Octreotide LAR was introduced in Europe in 1997 and was eventually approved by most Latin American Countries between 2000 and 2003. The most commonly used 20&#xA0;mg formulation has an approximate monthly cost that ranges from $1000 USD for government institutions that usually purchase large amounts of the medication, to up to $2000 USD for the individual private patient. Lanreotide autogel became available in several Latin American Countries as of 2008. The government price for the 90 and 120&#xA0;mg formulations is approximately $900 and $1200 USD, respectively. Lanreotide autogel&#x2019;s relatively easy administration can result in significant indirect cost savings, since the patient does not need to come monthly to a specialized facility in order to get his/her injection.</p>
        <p>A meta-analysis of prospective clinical trials up to the year 2003, suggests that long-acting SSAs reduce GH levels to &lt;2.5&#xA0;&#x3BC;g/L in just over 50&#xA0;% of patients and normalize IGF-1 levels in a similar proportion [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. However, it should be noted that these figures are derived mainly from studies with a pre-selection bias since, for the most part, they involved Caucasian patients previously responding to non-depot formulations of SSAs. As expected, response rates are lower among non-preselected patients [<xref ref-type="bibr" rid="CR2">2</xref>]. In a more recent multinational study looking at SSAs solely in unselected treatment-na&#xEF;ve patients, including participants from Latin America, a GH level&#xA0;&#x2264;&#xA0;2.5&#xA0;&#x3BC;g/L was achieved in 43&#x2013;44&#xA0;% and a normal age-adjusted IGF-1 in 34&#x2013;38&#xA0;% of patients (after 24 or 48&#xA0;weeks) and both goals were achieved in 25&#x2013;27&#xA0;% [<xref ref-type="bibr" rid="CR12">12</xref>]. Other longer-term studies in European, treatment-na&#xEF;ve populations have reported higher response rates for both GH (69&#x2013;100&#xA0;%) and IGF-1 (70&#x2013;98&#xA0;%), but these are likely to have been influenced by pre-selection bias and the use of per protocol rather than intention-to-treat analyses [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. To date, several predictors of biochemical response to SSAs have been identified, including gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5 [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
        <p>The SSAs are also effective at improving clinical symptoms of acromegaly, such as headache, fatigue, perspiration, and joint pain [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and have been shown to reduce the prevalence and severity of several measures of cardiomyopathy (arrhythmias, left ventricular hypertrophy, diastolic dysfunction and systolic dysfunction) and to improve certain cardiovascular risk factors, including hypertension and hypertriglyceridemia [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Interestingly, improvements in systolic function appear to be greatest when SSAs are used as primary therapy rather than after surgery, and it has been suggested that this may relate to a direct effect on the heart and/or better preservation of anterior pituitary function [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, SSAs induce clinically significant tumor shrinkage in close to 70&#xA0;% of primarily treated patients, and some evidence suggests that this rate is increased when using this analogs for long periods of time [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR22">22</xref>]. Dose optimization with SSAs has been shown to be an effective means to improve treatment outcomes in patients with acromegaly who have inadequate response to the starting dose or who fail to achieve complete control of their disease [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p>Dopamine agonists (principally cabergoline) may also be used as primary pharmacological therapy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Cabergoline has the advantage of oral administration and lower cost and may be the only available option if local resources are limited [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In a meta-analysis of 9 studies from the literature, cabergoline alone was able to normalize IGF1 in 34&#xA0;% of patients [<xref ref-type="bibr" rid="CR26">26</xref>]. The evidence does not support the commonly held view that dopamine agonists, which also suppress the secretion of prolactin, are more effective in patients with hyperprolactinemia (who may harbor mixed GH- and prolactin-secreting pituitary tumors) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Combination therapy with SSAs and dopamine agonists may be appropriate in cases of partial response to monotherapy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
        <p>Pharmacological therapy with the GH antagonist pegvisomant is generally restricted to patients with inadequate response or tolerability to SSAs [<xref ref-type="bibr" rid="CR4">4</xref>]. Although initial studies reported a close to 100&#xA0;% IGF-1 normalization rate, long-term studies reveal that this figure is between 60 and 70&#xA0;% [<xref ref-type="bibr" rid="CR27">27</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>]. The addition of pegvisomant 10&#x2013;30&#xA0;mg/day is another option that has proven to be effective in patients resistant to monthly injections of SSAs [<xref ref-type="bibr" rid="CR30">30</xref>]. Weekly and twice-weekly dosing (median dose 60&#xA0;mg/week) has also been shown to be effective and could reduce costs <italic>versus</italic> the currently approved daily dosing regimen [<xref ref-type="bibr" rid="CR31">31</xref>&#x2013;<xref ref-type="bibr" rid="CR33">33</xref>]. Pegvisomant is used, albeit as a tertiary option, in some (Venezuela, Argentina, Brazil) but not all Latin American Countries (Mexico, Chile, Colombia, Peru, Uruguay). Even at the lowest possible dose, the economic burden that represents the long-term treatment with pegvisomant can be overwhelming; the cost per month for a patient controlled on 10&#xA0;mg a day is between $7000 and $9000 USD.</p>
      </sec>
      <sec id="Sec4">
        <title>The combination treatment approach</title>
        <p>Rather than waiting for surgical approaches to fail before considering pharmacological therapy, another approach is the upfront consideration of pharmacological and surgical approaches together. Treatment with SSAs before TSS has been shown to improve surgical cure rates in patients with acromegaly [<xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR38">38</xref>]. However, not all studies have shown a benefit [<xref ref-type="bibr" rid="CR39">39</xref>&#x2013;<xref ref-type="bibr" rid="CR42">42</xref>], and the case for pre-surgical treatment with SSAs continues to be debated [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Similarly, as noted above, surgical debulking (in patients not initially amenable to complete surgical resection) has also been shown to improve the likelihood of biochemical control by SSAs [<xref ref-type="bibr" rid="CR45">45</xref>&#x2013;<xref ref-type="bibr" rid="CR49">49</xref>].</p>
        <p>Such combination approaches may be particularly appropriate for patients with advanced disease who may not be immediate candidates for surgery [<xref ref-type="bibr" rid="CR4">4</xref>]. In addition to reducing tumor size and improving the chances of successful surgical resection, pre-surgical treatment with SSAs, by virtue of improving soft tissue swelling and achieving control of co-morbidities (such as hypertension, cardiomyopathy and diabetes), may aid in reducing cardiopulmonary anesthetic risk and facilitate intubation (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Taba"><caption><p>Case study: Successful primary pharmacological therapy for a tumor with optic chiasm compression and limited chance of surgical cure (Source: Ana Laura Espinosa de los Monteros, MD)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">20&#xA0;year old male</td></tr><tr><td align="left">Progressive enlargement of hands and feet, as well as coarsening of facial features since age 15</td></tr><tr><td align="left">2&#xA0;years prior to consultation he developed headaches, fatigue and loud snoring</td></tr><tr><td align="left">For the past 4&#xA0;months he reports lack of morning erections and decreased libido</td></tr><tr><td align="left">No significant past medical history. He had progressed through puberty unremarkably. No known allergies</td></tr><tr><td align="left">Junior college student, actively engaged in sports. Does not smoke; no history of substance abuse</td></tr><tr><td align="left">Unremarkable family history</td></tr><tr><td align="left">
<italic>Physical examination</italic>
</td></tr><tr><td align="left">Pulse 67&#xA0;bpm, BP 134/76&#xA0;mmHg, Weight 103&#xA0;kg, Height 1.83&#xA0;m, BMI 30&#xA0;kg/m<sup>2</sup>
</td></tr><tr><td align="left">In no acute distress, evident acromegaloid features</td></tr><tr><td align="left">Enlarged supracilliary arches, prognathism, macroglossia, enlarged hands and feet</td></tr><tr><td align="left">Oily and thick skin, skin tags over anterior chest; no gynecomastia. Normal cardiopulmonary exam. No thyroid enlargement, no palpable lymph nodes; no palpable spleen or liver on abdominal examination. Gonadal exam appropriate for age and gender</td></tr><tr><td align="left">Normal visual fields by confrontation (confirmed by Goldmann and automated perimetry), isochoric pupils, reacting normally to light and accommodation; normal extraocular muscle movement; normal fundi</td></tr><tr><td align="left">
<italic>Hormonal evaluation</italic>
</td></tr><tr><td align="left">GH nadir during OGTT&#xA0;=&#xA0;5.3&#xA0;&#x3BC;g/L (2-h glucose&#xA0;=&#xA0;6.1&#xA0;mmol/L [110&#xA0;mg/dL])</td></tr><tr><td align="left">IGF-1: 1,110&#xA0;&#x3BC;g/L (3.5&#xA0;&#xD7;&#xA0;ULN)</td></tr><tr><td align="left">Prolactin: 191&#xA0;nmol/L (4,400&#xA0;&#x3BC;g/L [normal 3&#x2013;20&#xA0;&#x3BC;g/L])</td></tr><tr><td align="left">LH: 0.1&#xA0;IU/L (normal 1.7&#x2013;8.6&#xA0;IU/L)</td></tr><tr><td align="left">FSH: 0.3&#xA0;IU/L (normal 1.5&#x2013;12.4&#xA0;IU/L)</td></tr><tr><td align="left">Testosterone: 4.3&#xA0;nmol/L (125&#xA0;ng/dL [normal 280&#x2013;800&#xA0;ng/dL])</td></tr><tr><td align="left">TSH: 0.3 mIU/L (normal 0.4&#x2013;4.9 mIU/L)</td></tr><tr><td align="left">Free T4: 5.1&#xA0;pmol/L (0.4&#xA0;ng/dL [normal 0.8&#x2013;1.4&#xA0;ng/dL])</td></tr><tr><td align="left">Cortisol (8 AM): 254&#xA0;nmol/L (9.2&#xA0;&#x3BC;g/dL [normal 4.3&#x2013;22.4&#xA0;&#x3BC;g/dL])</td></tr><tr><td align="left">
<italic>Pre</italic>-<italic>treatment MRI</italic>
</td></tr><tr><td align="left">Gadolinium-enhanced, T1-weighted MRI, coronal view (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)</td></tr><tr><td align="left">5.5&#xA0;cm, hyperintense mass with a small cystic component</td></tr><tr><td align="left">Left parasellar extension with cavernous sinus invasion</td></tr><tr><td align="left">Suprasellar extension with optic chiasm compression</td></tr><tr><td align="left">
<italic>Treatment and course</italic>
</td></tr><tr><td align="left">SSA q. 4&#xA0;weeks, cabergoline 1.5&#xA0;mg q. week</td></tr><tr><td align="left">Levothyroxine 100&#xA0;&#x3BC;g QD, hydrocortisone 10&#xA0;mg BID</td></tr><tr><td align="left">Remarkable clinical improvement, persistence of sexual dysfunction</td></tr><tr><td align="left">
<italic>6</italic>&#xA0;<italic>month follow</italic>-<italic>up</italic>
</td></tr><tr><td align="left">GH: 1&#xA0;&#x3BC;g/L</td></tr><tr><td align="left">IGF-1: 365&#xA0;&#x3BC;g/L (1.15&#xA0;&#xD7;&#xA0;ULN)</td></tr><tr><td align="left">Prolactin: 304&#xA0;pmol/L (7&#xA0;&#x3BC;g/L)</td></tr><tr><td align="left">LH: 0.5&#xA0;IU/L; FSH: 1&#xA0;IU/L; testosterone: 6.9&#xA0;nmol/L (200&#xA0;ng/dL)</td></tr><tr><td align="left">Serum cortisol 83&#xA0;nmol/L (3&#xA0;&#x3BC;g/dL; after 5&#xA0;days of withholding hydrocortisone)</td></tr><tr><td align="left">
<italic>MRI after 6</italic>&#xA0;<italic>months of treatment</italic>
</td></tr><tr><td align="left">Gadolinium-enhanced, T1-weighted MRI, coronal view (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>)<break/>90&#xA0;% reduction of tumor, herniation of optic chiasm, aracnoidocele</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Case discussion</title>
      <p>This is a case of acromegaly due to a giant, mixed GH- and prolactin-secreting adenoma. In spite of cavernous sinus invasion and optic chiasm compression, the patient did not appear to have any significant mass effects from the tumor. The patient had a striking response to pharmacological treatment with combined SSA and dopamine agonist therapy in terms of GH/IGF-1 and prolactin normalization, as well as reduction in tumor volume. Upon presentation, this patient had a minimal chance of surgical cure due to supra and parasellar involvement (with cavernous sinus invasion) of the pituitary macroadenoma, and thus represented a good candidate for primary pharmacological therapy in line with current acromegaly treatment guidelines and consensus recommendations [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Upon long-term follow up, this young man was progressively able to first discontinue the dopamine agonist and, later-on, to reduce the dose of the SSA so after 3&#xA0;years, he only required 20&#xA0;mg of octreotide LAR every 2&#xA0;months to maintain a GH of around 1&#xA0;&#x3BC;g/L and an IGF-1 between 0.8 and 1.1&#xA0;&#xD7;&#xA0;ULN. This patient&#x2019;s increased responsiveness to the SSA as time went by is a well-established observation [<xref ref-type="bibr" rid="CR13">13</xref>] and undoubtedly has an important economic impact since the cost of therapy in the individual patient is significantly lowered. Considering that the adenoma almost disappeared with pharmacological therapy and the relatively low doses of SSA required by the patient to achieve biochemical control, we decided against submitting him to secondary management with either surgery or radiation therapy. Should this patient not have achieved biochemical and tumoral remission with pharmacological management, radiation therapy would have been an adequate option. Both conformal external beam radiation therapy [<xref ref-type="bibr" rid="CR52">52</xref>] and radiosurgery [<xref ref-type="bibr" rid="CR53">53</xref>] have proved to be effective and low-cost alternatives and undoubtedly are useful tools in the multi-modal strategy.</p>
      <p>Unfortunately, presentation with large, often inoperable tumors is encountered frequently in Latin America due to delays in diagnosis and this can limit the options offered to the patient, irrespective of the available resources [<xref ref-type="bibr" rid="CR3">3</xref>]. Nevertheless, this case provides a good example of how primary pharmacological therapy (in this instance using the combination of an SSA and a dopamine agonist) can be used to provide disease control in a patient with acromegaly who is initially not suitable for surgery. A major drawback of SSA is the need for long-term, indefinite therapy. In this regard, a substantial proportion of well-controlled patients can progressively increase their injection interval and a small but non-negligible number can eventually discontinue the drug [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
    </sec>
    <sec id="Sec6" sec-type="conclusions">
      <title>Conclusions</title>
      <p>Primary pharmacological therapy may be the only viable option for many patients with acromegaly, especially those presenting with advanced disease with large inoperable tumors, as often occurs in Latin America [<xref ref-type="bibr" rid="CR3">3</xref>]. In countries with limited resources, primary pharmacological therapy may also offer opportunities for disease control during delays in referrals for surgery. Many patients on primary pharmacological treatment will achieve good levels of biochemical control over the long-term, as well as decreased tumor size, improvements in symptoms and a reduction in severity of comorbidities.</p>
      <p>The current evidence suggests that only a quarter of patients receiving SSA therapy for at least a year will not achieve any significant improvement in GH and/or IGF-1 levels or a reduction in tumor size [<xref ref-type="bibr" rid="CR15">15</xref>]. Although a SSA is generally the drug of choice for first-line pharmacotherapy in acromegaly, in resource-poor regions, options may often be limited to cheaper, less effective drug classes. For instance, cabergoline may also be used as primary pharmacological therapy, especially if access to SSAs is limited.</p>
      <p>Although access to SSAs has improved in Latin America, the costs of pharmacological therapy remain an important issue and it is worth considering opportunities for improving the cost-effectiveness of SSA therapy 49]. For instance, strategies that proactively utilize pharmacological therapies in conjunction with surgery offer opportunities for improved rates of biochemical control and cure [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Furthermore, the use of drug combination therapy and/or extended dosing intervals may also help to improve response rates and reduce SSA doses [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Thus, although improved access to recommended therapies would be the ideal solution, Latin American clinicians may need a flexible approach in order to maximize the benefits of primary pharmacological therapy for acromegaly within their budget constraints and local access to drug resources.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The Latin American Knowledge Network Initiative, including meetings and preparation of this supplement, was organized and funded by Ipsen. Medical writing support was provided by Patrick Covernton on behalf of Arsenal-CDM Paris and funded by Ipsen. The authors were fully responsible for the concept and all content, were involved at all stages of manuscript development, and provided approval of the final version for submission.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acromegaly pathogenesis and treatment</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <issue>11</issue>
          <fpage>3189</fpage>
          <lpage>3202</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI39375</pub-id>
          <pub-id pub-id-type="pmid">19884662</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherlock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Medical therapy in acromegaly</article-title>
          <source>Nat Rev Endocrinol</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>5</issue>
          <fpage>291</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2011.42</pub-id>
          <pub-id pub-id-type="pmid">21448141</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>OD</given-names>
            </name>
            <name>
              <surname>Cob</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Espinosa-de-los-Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Garavito</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guitelman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mangupli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Portocarrero</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Management of acromegaly in Latin America: expert panel recommendations</article-title>
          <source>Pituitary</source>
          <year>2010</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>168</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-009-0206-y</pub-id>
          <pub-id pub-id-type="pmid">19882249</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists (2011) American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly&#x2013;2011 update. Endocr Pract 17(Suppl 4):1&#x2013;44
</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Uum S, Rivera J, Caspar-Bell G, Serri O (2012) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 2012 Nov 28. doi:10.1111/cen.12112. [Epub ahead of print]</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Molitch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kleinberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clemmons</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schlechte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Giustina</surname>
              <given-names>A</given-names>
            </name>
            <collab>Acromegaly Consensus Group</collab>
          </person-group>
          <article-title>Guidelines for acromegaly management: an update</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>5</issue>
          <fpage>1509</fpage>
          <lpage>1517</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-2421</pub-id>
          <pub-id pub-id-type="pmid">19208732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guinto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Abdo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zepeda</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ar&#xE9;chiga</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Acromegaly: role of surgery in the therapeutic armamentarium</article-title>
          <source>Int J Endocrinol</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>306094</fpage>
          <pub-id pub-id-type="doi">10.1155/2012/306094</pub-id>
          <pub-id pub-id-type="pmid">23209463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katznelson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Approach to the patient with persistent acromegaly after pituitary surgery</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2010</year>
          <volume>95</volume>
          <issue>9</issue>
          <fpage>4114</fpage>
          <lpage>4123</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-0670</pub-id>
          <pub-id pub-id-type="pmid">20823464</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hofland</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>van Aken</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lamberts</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>de Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Medical therapy of acromegaly: efficacy and safety of somatostatin analogues</article-title>
          <source>Drugs</source>
          <year>2009</year>
          <volume>69</volume>
          <issue>16</issue>
          <fpage>2207</fpage>
          <lpage>2226</lpage>
          <pub-id pub-id-type="doi">10.2165/11318510-000000000-00000</pub-id>
          <pub-id pub-id-type="pmid">19852525</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giustina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Casanueva</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ghigo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Klibanski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lamberts</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trainer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Current management practices for acromegaly: an international survey</article-title>
          <source>Pituitary</source>
          <year>2011</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>125</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-010-0269-9</pub-id>
          <pub-id pub-id-type="pmid">21063787</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freda</surname>
              <given-names>PU</given-names>
            </name>
            <name>
              <surname>Katznelson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Reyes</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rabinowitz</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Long-acting somatostatin analog therapy of acromegaly: a meta-analysis</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>8</issue>
          <fpage>4465</fpage>
          <lpage>4473</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-0260</pub-id>
          <pub-id pub-id-type="pmid">15886238</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borges</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bouterfa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Chervin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Farrall</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Patocs</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Petersenn</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Podoba</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Safari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wardlaw</surname>
              <given-names>J</given-names>
            </name>
            <collab>SMS995B2401 Study Group</collab>
          </person-group>
          <article-title>A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2007</year>
          <volume>66</volume>
          <issue>6</issue>
          <fpage>859</fpage>
          <lpage>868</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.02825.x</pub-id>
          <pub-id pub-id-type="pmid">17465997</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cozzi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Montini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Attanasio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Albizzi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lasio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lodrini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doneda</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cortesi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pagani</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9&#xA0;years) prospective study of its efficacy in the control of disease activity and tumor shrinkage</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <issue>4</issue>
          <fpage>1397</fpage>
          <lpage>1403</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-2347</pub-id>
          <pub-id pub-id-type="pmid">16449332</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Galdiero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Effects of initial therapy for 5&#xA0;years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>10</issue>
          <fpage>3746</fpage>
          <lpage>3756</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2009-0941</pub-id>
          <pub-id pub-id-type="pmid">19622615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Resistance to somatostatin analogs in acromegaly</article-title>
          <source>Endocr Rev</source>
          <year>2011</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>247</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1210/er.2010-0002</pub-id>
          <pub-id pub-id-type="pmid">21123741</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Kasuki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Korbonits</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Novel pathway for somatostatin analogs in patients with acromegaly</article-title>
          <source>Trends Endocrinol Metab</source>
          <year>2013</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>238</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tem.2012.11.007</pub-id>
          <pub-id pub-id-type="pmid">23270713</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Borson-Chazot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Blumberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maisonobe</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Delemer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Group</surname>
              <given-names>Lanreotide Acromegaly Study</given-names>
            </name>
          </person-group>
          <article-title>Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48&#xA0;weeks in patients with acromegaly</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2008</year>
          <volume>69</volume>
          <issue>2</issue>
          <fpage>299</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2008.03208.x</pub-id>
          <pub-id pub-id-type="pmid">18248639</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Galderisi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cappabianca</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Galdiero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>7</issue>
          <fpage>2639</fpage>
          <lpage>2646</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-0299</pub-id>
          <pub-id pub-id-type="pmid">18445662</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Improvement of cardiac parameters in patients with acromegaly treated with medical therapies</article-title>
          <source>Pituitary</source>
          <year>2012</year>
          <volume>15</volume>
          <issue>1</issue>
          <fpage>50</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-011-0318-z</pub-id>
          <pub-id pub-id-type="pmid">21713528</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amato</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mazziotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rotondi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iorio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sorvillo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Manganella</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Di Salle</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giustina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carella</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2002</year>
          <volume>56</volume>
          <issue>1</issue>
          <fpage>65</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1046/j.0300-0664.2001.01438.x</pub-id>
          <pub-id pub-id-type="pmid">11849248</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sternberg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Klibanski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonert</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Rhew</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kleinberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>7</issue>
          <fpage>4405</fpage>
          <lpage>4410</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2004-2466</pub-id>
          <pub-id pub-id-type="pmid">15827109</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giustina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mazziotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Torri</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Spinello</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Floriani</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Meta-analysis on the effects of octreotide on tumor mass in acromegaly</article-title>
          <source>PLoS ONE</source>
          <year>2012</year>
          <volume>7</volume>
          <issue>5</issue>
          <fpage>e36411</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0036411</pub-id>
          <pub-id pub-id-type="pmid">22574156</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fleseriu</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review</article-title>
          <source>Pituitary</source>
          <year>2011</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>184</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-010-0282-z</pub-id>
          <pub-id pub-id-type="pmid">21161602</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ludlam</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Anthony</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors</article-title>
          <source>Adv Ther</source>
          <year>2011</year>
          <volume>28</volume>
          <issue>10</issue>
          <fpage>825</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="doi">10.1007/s12325-011-0062-9</pub-id>
          <pub-id pub-id-type="pmid">21964965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherlock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fernandez-Rodriguez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Reulen</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Ayuk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clayton</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Holder</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>4</issue>
          <fpage>1255</fpage>
          <lpage>1263</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-1420</pub-id>
          <pub-id pub-id-type="pmid">19158203</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandret</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Maison</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Place of cabergoline in acromegaly: a meta-analysis</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <issue>5</issue>
          <fpage>1327</fpage>
          <lpage>1335</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-2443</pub-id>
          <pub-id pub-id-type="pmid">21325455</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schreiber</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Buchfelder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Droste</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Forssmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saller</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Strasburger</surname>
              <given-names>CJ</given-names>
            </name>
            <collab>German PegvisomantInvestigators</collab>
          </person-group>
          <article-title>Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study</article-title>
          <source>Eur J Endocrinol</source>
          <year>2007</year>
          <volume>156</volume>
          <issue>1</issue>
          <fpage>75</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.02312</pub-id>
          <pub-id pub-id-type="pmid">17218728</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trainer</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>ACROSTUDY: the first 5&#xA0;years</article-title>
          <source>Eur J Endocrinol</source>
          <year>2009</year>
          <volume>161</volume>
          <issue>Suppl 1</issue>
          <fpage>S19</fpage>
          <lpage>S24</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-09-0322</pub-id>
          <pub-id pub-id-type="pmid">19684052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>De Martino</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Bidlingmaier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Briganti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tortora</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Burman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kourides</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Strasburger</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance</article-title>
          <source>Eur J Endocrinol</source>
          <year>2006</year>
          <volume>154</volume>
          <issue>3</issue>
          <fpage>467</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.02112</pub-id>
          <pub-id pub-id-type="pmid">16498061</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feenstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>ten Have</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>van den Beld</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>365</volume>
          <issue>9471</issue>
          <fpage>1644</fpage>
          <lpage>1646</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)63011-5</pub-id>
          <pub-id pub-id-type="pmid">15885297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>van Aken</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>de Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2007</year>
          <volume>92</volume>
          <issue>12</issue>
          <fpage>4598</fpage>
          <lpage>4601</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1234</pub-id>
          <pub-id pub-id-type="pmid">17895318</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Bernabeu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cap</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neggers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Birman</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone</article-title>
          <source>Eur J Endocrinol</source>
          <year>2011</year>
          <volume>164</volume>
          <issue>3</issue>
          <fpage>325</fpage>
          <lpage>333</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-10-0867</pub-id>
          <pub-id pub-id-type="pmid">21148630</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barkan</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Chandler</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Hatfield</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Gebarski</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kelch</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Beitins</surname>
              <given-names>IZ</given-names>
            </name>
          </person-group>
          <article-title>Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1988</year>
          <volume>67</volume>
          <issue>5</issue>
          <fpage>1040</fpage>
          <lpage>1048</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem-67-5-1040</pub-id>
          <pub-id pub-id-type="pmid">2903168</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lucas-Morante</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Ur&#xED;a</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Estrada</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Saucedo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cabello</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alca&#xF1;iz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barcel&#xF3;</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery</article-title>
          <source>J Neurosurg</source>
          <year>1994</year>
          <volume>81</volume>
          <issue>1</issue>
          <fpage>10</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1994.81.1.0010</pub-id>
          <pub-id pub-id-type="pmid">8207509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stevenaert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Presurgical octreotide: treatment in acromegaly</article-title>
          <source>Metabolism</source>
          <year>1996</year>
          <volume>45</volume>
          <issue>Suppl 1</issue>
          <fpage>72</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1016/S0026-0495(96)90088-8</pub-id>
          <pub-id pub-id-type="pmid">8769388</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferone</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cappabianca</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Del De Basso Caro</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Marzullo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Monticelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alfieri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Merola</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cal&#xEC;</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Divitiis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Effect of octreotide pretreatment on surgical outcome in acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1997</year>
          <volume>82</volume>
          <issue>10</issue>
          <fpage>3308</fpage>
          <lpage>3314</lpage>
          <pub-id pub-id-type="pmid">9329359</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlsen</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lund-Johansen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aanderud</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Johannesen</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Svartberg</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Hald</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Fougner</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Bollerslev</surname>
              <given-names>J</given-names>
            </name>
            <collab>Preoperative Octreotide Treatment of Acromegaly Study Group</collab>
          </person-group>
          <article-title>Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cures short-term postoperative rates: a prospective, randomized trial</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>8</issue>
          <fpage>2984</fpage>
          <lpage>2990</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-0315</pub-id>
          <pub-id pub-id-type="pmid">18492760</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>ZG</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial</article-title>
          <source>Eur J Endocrinol</source>
          <year>2010</year>
          <volume>162</volume>
          <issue>4</issue>
          <fpage>661</fpage>
          <lpage>666</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-09-0908</pub-id>
          <pub-id pub-id-type="pmid">20061334</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biermasz</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>van Dulken</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Roelfsema</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1999</year>
          <volume>84</volume>
          <issue>10</issue>
          <fpage>3551</fpage>
          <lpage>3555</lpage>
          <pub-id pub-id-type="pmid">10522994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kristof</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Stoffel-Wagner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Klingm&#xFC;ller</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schramm</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly?</article-title>
          <source>A randomized study. Acta Neurochir (Wien)</source>
          <year>1999</year>
          <volume>141</volume>
          <issue>4</issue>
          <fpage>399</fpage>
          <lpage>405</lpage>
          <pub-id pub-id-type="doi">10.1007/s007010050316</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>L&#xFC;decke</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <article-title>Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre</article-title>
          <source>Eur J Endocrinol</source>
          <year>2001</year>
          <volume>145</volume>
          <issue>2</issue>
          <fpage>137</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.0.1450137</pub-id>
          <pub-id pub-id-type="pmid">11454508</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <mixed-citation publication-type="other">Pl&#xF6;ckinger U, Quabbe HJ (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case&#x2013;control study Acta Neurochir (Wien) 147(5):485&#x2013;493</mixed-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferone</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gatto</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Minuto</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for</article-title>
          <source>J Endocrinol Invest</source>
          <year>2012</year>
          <volume>35</volume>
          <issue>6</issue>
          <fpage>613</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="pmid">22776973</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Losa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crippa</surname>
              <given-names>VG</given-names>
            </name>
          </person-group>
          <article-title>Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against</article-title>
          <source>J Endocrinol Invest</source>
          <year>2012</year>
          <volume>35</volume>
          <issue>6</issue>
          <fpage>616</fpage>
          <lpage>618</lpage>
          <pub-id pub-id-type="pmid">22776974</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petrossians</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Borges-Martins</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Espinoza</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Betea</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Valdes-Socin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stevenaert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs</article-title>
          <source>Eur J Endocrinol</source>
          <year>2005</year>
          <volume>152</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.01824</pub-id>
          <pub-id pub-id-type="pmid">15762188</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Attanasio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cappabianca</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Lasio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lodrini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cozzi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <issue>1</issue>
          <fpage>85</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-1208</pub-id>
          <pub-id pub-id-type="pmid">16263832</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jallad</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Musolino</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Kodaira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cescato</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2007</year>
          <volume>67</volume>
          <issue>2</issue>
          <fpage>310</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.02885.x</pub-id>
          <pub-id pub-id-type="pmid">17555503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karavitaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Cudlip</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Byrne</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Fazal-Sanderson</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rowlers</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trainer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Wass</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2008</year>
          <volume>68</volume>
          <issue>6</issue>
          <fpage>970</fpage>
          <lpage>975</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.03139.x</pub-id>
          <pub-id pub-id-type="pmid">18031313</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Optimizing acromegaly treatment</article-title>
          <source>Front Horm Res</source>
          <year>2010</year>
          <volume>38</volume>
          <fpage>174</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="doi">10.1159/000318508</pub-id>
          <pub-id pub-id-type="pmid">20616509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vieira Neto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Abucham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Boguszewski</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Czepielewski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jallad</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Musolino</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Naves</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Ribeiro-Oliveira</surname>
              <given-names>A</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Vilar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Faria Mdos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil</article-title>
          <source>Arq Bras Endocrinol Metabol</source>
          <year>2011</year>
          <volume>55</volume>
          <issue>2</issue>
          <fpage>91</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="doi">10.1590/S0004-27302011000200001</pub-id>
          <pub-id pub-id-type="pmid">21584426</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abrams</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alexopoulou</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Abs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maiter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Verhelst</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Optimalization and cost management of lanreotide-Autogel therapy in acromegaly</article-title>
          <source>Eur J Endocrinol</source>
          <year>2007</year>
          <volume>157</volume>
          <issue>5</issue>
          <fpage>571</fpage>
          <lpage>577</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-07-0366</pub-id>
          <pub-id pub-id-type="pmid">17984236</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>de los Espinosa Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of radiotherapy in acromegaly</article-title>
          <source>Arch Med Res</source>
          <year>2011</year>
          <volume>42</volume>
          <fpage>48</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1016/j.arcmed.2011.01.004</pub-id>
          <pub-id pub-id-type="pmid">21376263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Attanasio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Epaminonda</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Motti</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Gamma-knife radiosurgery in acromegaly: a 4&#xA0;year follow-up study</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>3105</fpage>
          <lpage>3112</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2002-021663</pub-id>
          <pub-id pub-id-type="pmid">12843150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramirez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rabago</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>De los Espinosa Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?</article-title>
          <source>Eur J Endocrinol</source>
          <year>2012</year>
          <volume>166</volume>
          <fpage>21</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-11-0738</pub-id>
          <pub-id pub-id-type="pmid">21993154</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
